Frontiers in Oncology (Jan 2023)

Non-phosphorylatable mutants of Ser184 lead to incomplete activation of Bax

  • Lilit Simonyan,
  • Mathilde Gonin,
  • James Hanks,
  • Jordan Friedlein,
  • Kevin Dutrec,
  • Hubert Arokium,
  • Akandé Rouchidane Eyitayo,
  • Toukounou Megann Doudy,
  • Stéphane Chaignepain,
  • Stéphen Manon,
  • Laurent Dejean

DOI
https://doi.org/10.3389/fonc.2022.1068994
Journal volume & issue
Vol. 12

Abstract

Read online

The S184 residue of Bax is the target of several protein kinases regulating cell fate, including AKT. It is well-established that, in cellulo, the substitution of S184 by a non-phosphorylatable residue stimulates both the mitochondrial localization of Bax, cytochrome c release, and apoptosis. However, in in vitro experiments, substituted mutants did not exhibit any increase in their binding capacity to isolated mitochondria or liposomes. Despite exhibiting a significant increase of the 6A7 epitope exposure, substituted mutants remain limited in their ability to form large oligomers, suggesting that they high capacity to promote apoptosis in cells was more related to a high content than to an increased ability to form large pores in the outer mitochondrial membranes.

Keywords